Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia 11Prostatic Neoplasms 9Breast Neoplasms 9Leukemia, Myeloid, Acute 8Leukemia, Lymphocytic, Chronic, B-Cell 7Neuroblastoma 6Myelodysplastic Syndromes 6Multiple Myeloma 6Melanoma 6Lymphoma 6Glioblastoma 6Ovarian Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Glioma 4Osteosarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms, Male 3Neoplasms, Plasma Cell 2Neoplasms 2Medulloblastoma 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

Carboplatin 42Etoposide 37Cisplatin 23Topotecan 22Nivolumab 17pembrolizumab 12atezolizumab 12Ipilimumab 10Paclitaxel 9durvalumab 8Irinotecan 8Radiosurgery 6Pemetrexed 6rovalpituzumab tesirine 5Magnetic Resonance Spectroscopy 5trioctyl phosphine oxide 4trilaciclib 4etoposide phosphate 4berzosertib 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4Dexamethasone 4veliparib 3tremelimumab 3olaparib 3carfilzomib 3cabozantinib 3Temozolomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Small Cell Lung Carcinoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡